A-Alpha Bio is a technology company.
A-Alpha Bio is a technology company.
A-Alpha Bio has raised $42.0M across 2 funding rounds.
A-Alpha Bio has raised $42.0M in total across 2 funding rounds.
A-Alpha Bio has raised $42.0M in total across 2 funding rounds.
A-Alpha Bio's investors include Breakout Ventures, Madrona Ventures, VZVC.
A-Alpha Bio is a biotechnology company that develops platforms for measuring, predicting, and engineering protein-protein interactions using synthetic biology and machine learning to accelerate therapeutic discovery.[1][3] Its core products, AlphaSeq and AlphaBind, enable high-throughput measurement of millions of interactions and AI-driven predictions from sequence data, serving pharmaceutical partners and in-house programs targeting cancers, infectious diseases, and neurological disorders.[1][3] The company solves the critical lack of high-quality protein interaction data, fueling antibody discovery, protein degradation, and drug optimization, with billions of interactions measured to date and partnerships with leading pharma firms indicating strong growth momentum.[3]
A-Alpha Bio was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology in Seattle, Washington.[1][6] Co-founders David Younger, PhD (CEO) and Randolph Lopez, PhD (CTO) led the effort, drawing from their expertise in protein design and synthetic biology.[1][5] The idea emerged from academic roots, evolving into a platform company focused on large-scale protein interaction screening, with early traction through building the world's largest such database and attracting investors like Madrona Venture Group and Breakout Ventures.[1][5]
A-Alpha Bio rides the convergence of synthetic biology, AI, and precision medicine, addressing a data bottleneck in understanding disease-driving protein interactions amid rising demand for targeted therapies.[3] Timing aligns with advances in ML for biology (e.g., protein folding predictions) and pharma's shift to high-throughput platforms, amplified by post-pandemic focus on rapid drug discovery for oncology and neurodegeneration.[1][3] Market forces like exploding biologics pipelines and AI-biotech investments favor it, as its data repository uniquely trains predictive models, influencing the ecosystem by enabling faster, cheaper therapeutic iteration for partners.[3][5]
A-Alpha Bio is poised to expand its platform through deeper pharma collaborations and potential in-house clinical candidates, leveraging its data moat for next-gen modalities like molecular glues and engineered antibodies.[1][3] Trends in AI-driven drug design and synthetic biology scale-up will propel growth, potentially leading to Series B+ funding or acquisitions by big pharma seeking interaction prediction tech. Its influence could evolve from data provider to full-stack therapeutics engine, transforming how protein-based medicines are discovered. This positions A-Alpha Bio as a key player at the intersection of computation and biology, directly tackling unmet needs in human health.[3][5]
A-Alpha Bio has raised $42.0M across 2 funding rounds. Most recently, it raised $22.0M Series A in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $22.0M Series A | Breakout Ventures, Madrona Ventures, VZVC | |
| Sep 1, 2021 | $20.0M Series A | Madrona Ventures, VZVC |